Literature DB >> 10948662

Validation of a new technique to assess exhaled hydrogen peroxide: results from normals and COPD patients.

F De Benedetto1, A Aceto, B Dragani, A Spacone, S Formisano, R Cocco, C M Sanguinetti.   

Abstract

Chronic airways inflammation in chronic obstructive pulmonary disease (COPD) induces the activation of several cell types with delivery of proteases and reactive oxygen species (ROS). Assessing oxidant content in the exhaled air of COPD patients has proven useful in monitoring airway inflammation. The present study was designed to confirm the usefulness of exhaled hydrogen peroxide concentration determination in COPD patients using a new technique which allows longer storage of the expired air condensate before the H2O2 assay. The technique was applied in 13 healthy nonsmoking subjects (six male, age range 22-40 yrs) and in seven patients (five male, age range 58-81 yrs) with mild or moderate COPD. Subjects breathed into a one-valve mouthpiece, and the exhaled air was directed into a vial kept at 0 degree C. After approximately 15 min of quiet breathing, 1 mL of expired air condensate was collected. An aliquot, 450 microL, of this sample was immediately added to an equal volume of a reaction mixture containing 2 mM 3,5,3',5'-tetramethylbenzidine and 40 microL of enzyme stock solution (0.5 mg.mL-1). After 15 min, 45 microL sulphuric acid was added (1 N final concentration), resulting in a reaction mixture pH of 1.0. After a further 10-min incubation, H2O2 concentration determination was performed spectrophotometrically at 450 nm. This solution, as well as the H2O2 assay, was stable for > or = 24 h if the sample was kept in the dark and at 4 degrees C. There was high stability on repeated measures, with a coefficient of variation equal to zero. The mean +/- SD H2O2 level in exhaled air from normal subjects was 0.12 +/- 0.09 microM, whereas it was significantly increased in COPD patients (0.50 +/- 0.11 microM; p = 0.0001 compared to healthy subjects). In three healthy control subjects, a normal H2O2 level in expired air increased to 0.70-0.80 microM during an acute upper respiratory tract infection. This new technique of hydrogen peroxide assay in expired air condensate greatly minimizes the inaccuracy deriving from the instability of hydrogen peroxide. The preliminary results obtained using this technique provide direct evidence for increased reactive oxygen species production in the airways of stable chronic obstructive pulmonary disease patients. However, the specificity of the procedure could be reduced by the interference of upper respiratory tract infections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10948662

Source DB:  PubMed          Journal:  Monaldi Arch Chest Dis        ISSN: 1122-0643


  7 in total

1.  Chemiluminescent Measurement of Hydrogen Peroxide in the Exhaled Breath Condensate of Healthy and Asthmatic Adults.

Authors:  Miguel E Quimbar; Steven Q Davis; Sherif T Al-Farra; Amanda Hayes; Valentina Jovic; Maximillian Masuda; Alexander R Lippert
Journal:  Anal Chem       Date:  2020-10-16       Impact factor: 6.986

2.  Measured Pulmonary and Systemic Markers of Inflammation and Oxidative Stress Following Wildland Firefighter Simulations.

Authors:  Matthew D Ferguson; Erin O Semmens; Charles Dumke; John C Quindry; Tony J Ward
Journal:  J Occup Environ Med       Date:  2016-04       Impact factor: 2.162

Review 3.  Mechanisms and function of DUOX in epithelia of the lung.

Authors:  Horst Fischer
Journal:  Antioxid Redox Signal       Date:  2009-10       Impact factor: 8.401

4.  Hydrogen peroxide release and acid-base status in exhaled breath condensate at rest and after maximal exercise in young, healthy subjects.

Authors:  E Marek; P Platen; J Volke; K Mückenhoff; W Marek
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

5.  The influence of hydrogen peroxide and histamine on lung permeability and translocation of iridium nanoparticles in the isolated perfused rat lung.

Authors:  James J Meiring; Paul J A Borm; Karim Bagate; Manuela Semmler; Jürgen Seitz; Shinji Takenaka; Wolfgang G Kreyling
Journal:  Part Fibre Toxicol       Date:  2005-06-27       Impact factor: 9.400

Review 6.  N-acetylcysteine in COPD: why, how, and when?

Authors:  Claudio M Sanguinetti
Journal:  Multidiscip Respir Med       Date:  2016-02-03

Review 7.  Clinical use of exhaled biomarkers in COPD.

Authors:  Philip O'Reilly; William Bailey
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.